Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors.

de Britto Evangelista, Guilherme Ferreira; Figueiredo, Amanda Braga; de Barros E Silva, Milton José; Gollob, Kenneth J

de Britto Evangelista, Guilherme Ferreira; Figueiredo, Amanda Braga; de Barros E Silva, Milton José; Gollob, Kenneth J.

Afiliación

de Britto Evangelista GF; Translational Immuno-oncology Laboratory, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Figueiredo AB; Translational Immuno-oncology Laboratory, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
de Barros E Silva MJ; Clinical Oncology Department, A.C.Camargo Cancer Center, São Paulo, SP, Brazil.
Gollob KJ; Translational Immuno-oncology Laboratory, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Immunother Adv ; 2(1): ltac008, 2022.

Article en En | MEDLINE | ID: mdl-35919497

Palabras clave

T-cells; adverse events; autoimmunity; cancer immunotherapy; checkpoint inhibitors; immune mechanisms; toxicity

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Immunother Adv Año: 2022 Tipo del documento: Article País de afiliación: Brasil

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google